Autoimmune Atrial Fibrillation

Ange Maguy, PhD; Yuvaraj Mahendran, PhD; Jean-Claude Tardif, MD; David Busseuil, PhD; Jin Li, MD

BACKGROUND: Atrial fibrillation (AF) is by far the most common cardiac arrhythmia. In about 3% of individuals, AF develops as a primary disorder without any identifiable trigger (idiopathic or historically termed lone AF). In line with the emerging field of autoantibody-related cardiac arrhythmias, the objective of this study was to explore whether autoantibodies targeting cardiac ion channels can underlie unexplained AF.

METHODS: Peptide microarray was used to screen patient samples for autoantibodies. We compared patients with unexplained AF (n=37 pre-existent AF; n=14 incident AF on follow-up) to age- and sex-matched controls (n=37). Electrophysiological properties of the identified autoantibody were then tested in vitro with the patch clamp technique and in vivo with an experimental mouse model of immunization.

RESULTS: A common autoantibody response against Kir3.4 protein was detected in patients with AF and even before the development of clinically apparent AF. Kir3.4 protein forms a heterotetramer that underlies the cardiac acetylcholine-activated inwardly rectifying K+ current, I_{K_ACh}. Functional studies on human induced pluripotent stem cell–derived atrial cardiomyocytes showed that anti-Kir3.4 IgG purified from patients with AF shortened action potentials and enhanced the constitutive form of I_{K_ACh}, both key mediators of AF. To establish a causal relationship, we developed a mouse model of Kir3.4 autoimmunity. Electrophysiological study in Kir3.4-immunized mice showed that Kir3.4 autoantibodies significantly reduced atrial effective refractory period and predisposed animals to a 2.8-fold increased susceptibility to AF.

CONCLUSIONS: To our knowledge, this is the first report of an autoimmune pathogenesis of AF with direct evidence of Kir3.4 autoantibody-mediated AF.

Key Words: atrial fibrillation • autoantibody • autoimmunity • I_{K_ACh} • Kir3.4

Atrial fibrillation (AF) is an ever-growing pandemic, with >46.3 million affected individuals worldwide. Thromboembolism and heart failure are the major complications, associated with increased mortality. Cardiovascular risk factors (eg, obesity, arterial hypertension, and diabetes) contribute to the development of AF, whereas structural heart diseases and valvulopathies represent common underlying causes. Nevertheless, it is estimated that an underlying pathogenesis cannot be found in at least 3% of patients with AF. Contrary to past assumptions, emerging evidence portends the involvement of autoantibodies in cardiac arrhythmias. Because cardiac ion channels are key regulators of the heart rhythm, any perturbation of their function disrupts cardiac electrophysiology and can eventually trigger arrhythmias. Anti-Ro/SSa IgG is an archetypal autoantibody leading to cardiac conduction diseases, whereas autoantibodies binding to calcium and potassium channels (eg, Ca_{1.2}, K_{7.1}, and K_{11.1}) have been implicated in ventricular arrhythmias.

In the present study, we sought to identify an autoantibody signature of AF using high-throughput microarray
Clinical Perspective

What Is New?
• This is the first study to systematically screen patients with atrial fibrillation (AF) for the presence of autoantibodies targeting cardiac ion channels.
• K$_{3.4}$ autoantibodies are detected in patients with unexplained AF.
• K$_{3.4}$ autoantibodies increase $I_{K_{ACh}}$ current to shorten atrial repolarization and induce AF.

What Are the Clinical Implications?
• The present study introduces a novel form of autoimmune AF, caused by K$_{3.4}$ autoantibodies.
• The diagnosis of an autoimmune AF suggests that affected patients may benefit from a fundamentally different treatment approach than traditional AF.

Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>AERP</th>
<th>atrial effective refractory period</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>APD</td>
<td>action potential duration</td>
</tr>
<tr>
<td>Ca$_d$</td>
<td>voltage-gated calcium channel</td>
</tr>
<tr>
<td>hiPSC-aCMC</td>
<td>human induced pluripotent stem cell–derived atrial cardiomyocyte</td>
</tr>
<tr>
<td>$I_{Ca,L}$</td>
<td>L-type calcium current</td>
</tr>
<tr>
<td>$I_{K_{ACh}}$</td>
<td>acetylcholine-activated inwardly rectifying potassium current</td>
</tr>
<tr>
<td>$I_{Kur}$</td>
<td>ultrarapid delayed rectifier potassium current</td>
</tr>
<tr>
<td>$I_{K1}$</td>
<td>inward rectifier potassium current</td>
</tr>
<tr>
<td>$I_{Na}$</td>
<td>sodium current</td>
</tr>
<tr>
<td>$I_{to}$</td>
<td>transient outward potassium current</td>
</tr>
<tr>
<td>K$_{ir}$</td>
<td>inwardly rectifying potassium channel</td>
</tr>
<tr>
<td>K$_V$</td>
<td>voltage-gated potassium channel</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricular</td>
</tr>
<tr>
<td>LVID</td>
<td>left ventricular internal diameter</td>
</tr>
<tr>
<td>MiRP</td>
<td>MinK-related peptide</td>
</tr>
<tr>
<td>pre-AF</td>
<td>incident atrial fibrillation during follow-up</td>
</tr>
<tr>
<td>s</td>
<td>end-systole</td>
</tr>
</tbody>
</table>

METHODS

The data, analytical methods, and study materials are made available to other researchers for purposes of reproducing the results and replicating the procedure. All data that support the findings of this study are made publicly available at the ZENODO repository and can be accessed at doi: 10.5281/zenodo.7491428.

Patient Samples

The study was conducted in accordance with the Declaration of Helsinki and the guidelines of Good Clinical Practice issued by the International Conference on Harmonization. Institutional review board approval and informed consent by the patient were obtained. Plasma samples used in this study were collected from patients diagnosed with unexplained AF (either pre-existent, referred to as AF, or incident during follow-up, referred to as pre-AF) and age-/sex-matched healthy individuals (referred to as controls). Unexplained AF was defined as AF in the absence of a direct underlying cause, in terms of secondary AF, such as structural heart disease, valvulopathies, or thyroid dysfunction. Modifiable cardiovascular risk factors (eg, arterial hypertension, diabetes, dyslipidemia, and obesity) were not considered criteria of exclusion to obtain data from subjects, representative of real-world populations, in which these factors often coexist. Detailed Methods are provided in the Supplemental Material.

Peptide Microarray Assay

Peptides corresponding to extracellular sequences of all cardiac ion channels were translated into PEPperCHIP Custom Peptide Microarrays (PEPperPRINT GmbH, Heidelberg, Germany), as previously described. Because anti-M$_2$-muscarinic acetylcholine and anti-$\beta$-adrenergic receptor autoantibodies have been associated with AF, both peptide sequences were included in the microarray assays. Briefly, all plasma samples were diluted 1:30, followed by incubation with secondary (goat antihuman IgG [Fc] DyLight680) and control antibody (mouse monoclonal antihemagglutinin [12CA5] to confirm assay quality and the peptide microarray integrity). The LI-COR Odyssey Imaging System was used for scanning and readout. Microarray images were analyzed with the PepSlide Analyzer, as detailed previously.

IgG Purification

Anti-K$_{3.4}$ autoantibodies were purified from pooled plasma of patients with AF with anti-K$_{3.4}$ IgG responses using affinity chromatography. The target K$_{3.4}$ peptide was immobilized through click chemistry through a C-terminal Lys(Azide) to dibenzocyclooctyne-functionalized column matrix (Peptide Specialty Laboratories GmbH, Heidelberg, Germany). Pooled plasma samples were diluted 1:1 with 1×PBS and applied onto the columns overnight at 4 °C with slow rotation. The total effluent was then run through the column twice. After several washing steps (3×1×PBS; 2×10 mmol/L Na-phosphate pH 6.8), the IgG antibodies were eluted from the column using Pierce IgG Elution Buffer (ThermoFisher Scientific, Zug, Switzerland) and collected in 2 mol/L K$_2$HPO$_4$. A diafiltration step was performed to transfer the purified IgGs into sterile 1×PBS pH 7.4.

technology. We then performed patch clamp experiments to assess the electrophysiological properties of detected autoantibodies on atrial cardiomyocytes. Finally, we validated the arrhythmogenicity of detected autoantibodies in an experimental mouse model of immunization.
The antibody concentrations were determined with a bicinchoninic acid assay (QuantiPro BCA Assay Kit, Sigma Aldrich GmbH, Buchs, Switzerland).

**Human Induced Pluripotent Stem Cell–Derived Atrial Cardiomyocytes**

Human induced pluripotent stem cell–derived cardiomyocytes with an atrial phenotype (hiPSC-aCMCs) were custom manufactured and provided by Ncardia BV (Leiden, The Netherlands). HiPSC-aCMCs were cultured according to manufacturer instructions, as previously described.11–13 Further details on the atrial phenotype and handling of hiPSC-aCMCs are provided in the Supplemental Material. Pluricyte Cardiomyocyte Medium was changed every 48 hours until downstream patch clamp experiments (between days 7 and 12). Cells treated with anti-K$_{\text{ATP}}$ 3.4 IgG (0.5 µg/mL) were preincubated for 24 hours before electrophysiological measurements.

**Whole-Cell Patch Clamp Experiments**

Patch clamp experiments were performed with EPC-10 amplifier controlled by PATCHMASTER (HEKA Elektronik GmbH, Lambrecht, Germany) to record cardiac action potentials and the acetylcholine-regulated inward rectifier K$^+$ current, $I_{\text{KAC}}$.11–15 All measurements were performed at 37 °C. In brief, to record action potentials on spontaneously beating cardiomyocytes under current clamp conditions, the following external (Tyrode) solution was used (mmol/L): 140 NaCl, 5 KCl, 1 MgCl$_2$, 10 HEPES, 1.8 CaCl$_2$, 10 glucose (pH 7.4 adjusted with NaOH); anti-K$_{\text{ATP}}$ 3.4 IgG (0.5 µg/mL). Filamented borusilicate glass pipettes (tip resistances 2–4 MOhm, Harvard Apparatus, Holliston, MA) were filled with (mmol/L) 110 K$^+$-aspartate, 20 KCl, 1 MgCl$_2$, 5 Mg$^{2+}$-ATP, 0.1 Li$^+$-GTP, 10 HEPES, 5 Na$^+$-phosphocreatine, 0.05 EGTA (pH 7.3 adjusted with KOH), and 200 µg/mL amphotericin B. To record $I_{\text{KAC}}$, 10 µmol/L nifedipine (to inhibit the L-type Ca$^{2+}$ current, $I_{\text{Ca,L}}$), 2 mmol/L 4-aminopyridine (to suppress the ultrarrapid outward current, $I_{\text{Na}}$), and the transient outward current, $I_{\text{to}}$, and 10 µmol/L ML-133 (Alomone Labs, Jerusalem, Israel, to block the background inward rectifier current, $I_{\text{g}}$) were added to the Tyrode external solution; anti-K$_{\text{ATP}}$ 3.4 IgG (0.5 µg/mL). Of note, Tertiapin Q, a selective inhibitor of $I_{\text{KAC}}$, has been traditionally used in patch clamp studies to record $I_{\text{KAC}}$ current after a digital subtraction step of $I_{\text{g}}$ out of the inward rectifier K$^+$ current. Because Tertiapin Q binds to the extracellular pore loop domain and vice versa, both share the same extracellular target site, so the coadministration would potentially result in binding competition (eg, through steric hindrance). To circumvent this issue, we therefore applied ML-133, a novel selective $I_{\text{g}}$, inhibitor, to directly record $I_{\text{KAC}}$.14 Borosilicate glass capillaries with tip resistances of 5 to 7 MOhm were filled with internal solution composed of (mmol/L) 110 K$^+$-aspartate, 20 KCl, 1 MgCl$_2$, 5 Mg$^{2+}$-ATP, 0.1 Li$^+$-GTP, 10 HEPES, 5 Na$^+$-phosphocreatine, and 5 EGTA (pH 7.3 adjusted with KOH). To stimulate $I_{\text{KAC}}$, the nonselective agonist carbobalrol, 10 µmol/L, was applied. For each set of experiments, measurements were collected between 10 and 120 minutes. The liquid junction potential was compensated (12.4 mV). The action potential duration (APD) at 90% repolarization, maximum diastolic potential, action potential amplitude, and beating rates were determined with FITMASTER (HEKA Elektronik GmbH, Lambrecht, Germany). $I_{\text{KAC}}$ currents were elicited with a holding potential of −40 mV (to prevent the activation of the sodium current, $I_{\text{Na}}$), followed by 4-s test pulses between −120 mV and −20 mV in 10 mV-incremental steps. $I_{\text{KAC}}$ currents were expressed as densities (pA/pF) to normalize for cell size. $I_{\text{KAC}}$ data were analyzed with FITMASTER.

**Study Animals and Design**

Experiments were performed on Balb/c mice (8 weeks of age at first immunization; Charles River, France). Male and female mice were used in equal proportions. Immunization was carried out by BIOTEM (Apprieu, France) in accordance with a previously described protocol.12–17 The peptide (IETETTIGFRVITEKPEC) was synthesized by BIOTEM (Apprieu, France). Of note, the target amino acid sequence is highly conserved between human and murine K$_{\text{ir3.4}}$ protein. Because the peptide contains an internal cysteine, a protected cysteine (C) was added during synthesis (IETETTIGFRVITEKPEC) and deprotected after coupling to the carrier protein KLH. Mice from the K$_{\text{ir3.4}}$-immunized group received a subcutaneous injection of 100 µg of peptide supplemented with Complete Freund Adjuvant (day 0), followed by weekly injections of 50 µg of peptide and Incomplete Freund Adjuvant on days 7, 14, and 21. Mice from the control group were subjected to sham immunization (ie, Complete Freund Adjuvant and Incomplete Freund Adjuvant injections without peptide). ELISA was performed to quantify the IgG antibody titers on day 28 (Supplemental Material). All animals then underwent an echocardiographic assessment of their cardiac function as well as in vivo electrophysiological study. All animal procedures followed the guidelines of the Ethics Committee for Animal Experimentation of the Swiss Academy of Medical Sciences and the Swiss Academy of Sciences (BE97/2021).

**Transthoracic Echocardiography**

Echocardiograms were obtained using a 15L8-S transducer (15-8MHz) connected to the Acuson Sequoia C512 system (Siemens Healthcare AG, Switzerland) with the echocardiographer blinded to the group allocation of the animals. All mice were anesthetized with isoflurane (3.5% for induction and 1.5%-2% for maintenance) mixed with 2 L/min oxygen. Core temperature was maintained at 37 °C. Left ventricular internal diameter (LVID), anterior and posterior left ventricular (LV) wall thickness, both at end-diastole (d) and end-systole (s), were measured using the M-mode in short-axis view, at the level of the papillary muscle. LV fractional shortening was calculated as fractional shortening (%) = $100 \times \frac{(LVID_d - LVID_s)}{LVID_d}$. Whereas LV ejection fraction was calculated as ejection fraction (%) = $100 \times \left(\frac{LVID_d - LVID_s}{LVID_d}\right)^3$.18 Left atrial diameter was obtained with B-mode in the parasternal long-axis view.

**Electrocardiography and Electrophysiological Study**

Anesthesia was induced with 3.5% isoflurane and maintained at 1.5% to 2% isoflurane with 2 L/min oxygen flow rate. The body temperature was kept at 37 °C with a heating pad, and

Circulation. 2023;148:00–00. DOI: 10.1161/CIRCULATIONAHA.122.062776 xxx xxx, 2023 3
all mice were continuously monitored with surface 3-lead ECG connected to the data acquisition system PowerLab (16/35, ADInstruments Ltd, United Kingdom). 29-Gauge needle electrodes were placed at the base of the limbs. Baseline ECG intervals (RR, PR, QRS, QT, and JT) were calculated in lead I or II for each animal, on the basis of averages of 10 consecutive complexes. The formula proposed by Mitchell et al was used for heart rate correction of the QT and JT intervals: QTc = QT/\((RR/100)^{1/2}\) and JTc = JT/(RR/100)^{1/2}, respectively. A 1.1F octapolar electrophysiology catheter (ADInstruments Ltd, United Kingdom) was inserted into the right internal jugular vein to record intracardiac electrograms. Bipolar electrogram recordings were obtained from the right atrium and the right ventricle (sampling rate 4 kHz, filtered between 0.5 and 500 Hz). Stimulation was performed with 2-ms pulse width at twice the diastolic threshold. Standard electrophysiological pacing protocols were adopted to measure basic parameters.\(^{18,21,22}\) To evaluate the sinus node function, the right atrium was paced at 100 ms during 15 s. Sinus node recovery time was defined as the time interval between the last stimulus of pacing train and the onset of first spontaneous atrial signal. Corrected sinus node recovery time was calculated as the difference between sinus node recovery time and the sinus cycle length before stimulation. We determined the atrioventricular conduction properties with rapid atrial pacing of 2-s durations, starting at a basic cycle length of 100 ms and decrements of 10-ms intervals. The antragerode Wenckebach cycle length was defined as the pacing rate at which the loss of 1:1 atrioventricular conduction occurs. To assess effective refractory periods of the atrium and the atrioventricular node (AERP and atrioventricular effective refractory period, respectively), the atrium was stimulated with a train of 9 stimuli at a fixed pacing cycle length (S1) of 100 ms followed by an extrastimulus (S2) introduced at progressively shorter coupling intervals. The stepwise reduction in S1-S2 interval by 2-ms decrements started at 70 ms until S2 no longer conducted to the ventricles through the atrioventricular node (atrioventricular effective refractory period) and until S2 no longer induced an atrial signal (AERP; minimum coupling interval of 20 ms). Inducibility of AF was tested by using standard burst pacing protocols, as previously described.\(^{18,21,23}\) Briefly, 2-s bursts with decremental cycle lengths of 40 ms to 20 ms (in 2-ms steps) were applied. Next, atrial burst pacing was performed with 300 cycles of 2-ms bursts and a cycle length of 50 ms, 40 ms, 30 ms, 20 ms, and 10 ms. AF was defined as lack of regular P-waves and irregularly irregular QRS complexes on ECG, in combination with rapid, fragmented atrial electrograms with irregular ventricular rhythm, lasting at least 2 s. If 1 or more bursts in either protocol evoked an AF episode, AF was considered to be inducible in that animal. The investigator performing and analyzing the electrophysiological study was blinded to the group assignment of the mice. All data were analyzed using LabChart 8 software (ADInstruments Ltd, United Kingdom).

Statistical Analysis

The statistical analysis of microarrays was based on the background-corrected median intensities of IgG responses against a hundred different peptides. Data analysis was performed with R language (R version 4.0.2). A positive response was defined as ≥100 fluorescence intensity units, and signals <100 fluorescence intensity units were set as 0, accordingly. Peptides with 0 fluorescence intensity units in all individuals were removed, and the remaining 84 peptides were used for statistical analysis. The remaining raw values of IgG of the 84 peptides were normalized using variance stabilizing normalization.\(^{24}\) The variance stabilizing normalized data were used for 1-way ANOVA to identify differential IgG responses in AF and pre-AF versus control, respectively. We defined false discovery rate adjusted P values of <0.10 as threshold for statistical significance of an IgG response, using the Benjamini-Hochberg correction method. In addition, a principal component analysis was performed with the microarray data to visualize pattern between samples and identify clustering in patients with AF according to IgG profiles.

Electrophysiological in vitro and in vivo data were tested for normality with the Shapiro-Wilk test. Normally distributed patch clamp data of similar variance were compared by 1-way ANOVA, followed by Tukey post hoc test. The Kruskal-Wallis test was used when the normality assumption was not met with the Dunn multiple-comparisons test. Because data derived from the murine model (echocardiography, ECG, and electrophysiological study) compared sham- with K\(_{ir}3.4\)-immunized mice, parametric data were analyzed with the Student t test, whereas nonparametric parameters were compared with the Mann-Whitney U test. Categorical variables (AF inducibility) were compared using the Fisher exact test. Statistical analyses were performed with GraphPad Prism 9 (GraphPad Software, Inc, La Jolla, CA). A P value < 0.05 was considered statistically significant.

RESULTS

Study Population

Thirty-seven patients diagnosed with unexplained AF were age- and sex-matched with 37 healthy controls (Table S1). The patient demographics included 34 female and 40 male participants, with a mean age of 69.8±16.4 years. Another 14 patients (pre-AF) had no documented AF at baseline but developed unexplained AF during a mean follow-up of 52 months. Before the diagnosis of AF, patients were in the same age range (67.5±7.5 years) as the cohort with established AF (P=0.822; Table S1).

Autoantibody Signature of AF

A tailored peptide microarray was used to map the IgG responses to cardiac ion channels in patients with and without AF (Table S2). Figure 1 illustrates the analysis workflow. In general, we observed autoantibody responses in all 3 groups, with higher reactivities in patients with AF compared with pre-AF and healthy subjects. The principal component analysis did not show any particular clustering of AF and pre-AF samples (Figure S1). The results of 1-way ANOVA were sorted by decreasing mean differences and summarized in Table 1. We found statistically significant autoantibodies reacting with the IETETTIGYFRVITEKCPE (K\(_{ir}3.4\) protein) and...
Figure 1. Overview of analysis workflow.
Diagram showing the analysis workflow of the present study; 37 patients with AF, 37 age- and sex-matched healthy controls, and 14 patients before the development of AF (pre-AF) were enrolled. Using peptide microarray, plasma samples were screened for the presence of autoantibodies targeting a panel of cardiac ion channels. The heat map of peptides was analyzed for immunoreactivity across all plasma samples. The identified autoantibody was then purified using affinity chromatography and tested on human atrial cardiomyocytes. Mice immunized with the target peptide produced autoantibodies to replicate the human condition. No structural heart abnormalities were evident, and electrophysiological in vivo study confirmed an increased AF susceptibility in immunized mice. AF indicates atrial fibrillation; EP, electrophysiological; iPS, induced pluripotent stem cell; and SR, sinus rhythm.
SNFTQLEDVFRRIFTYM (MiRP protein [MinK-related peptide]) peptides in patients with AF, whereas anti-LMVTMSTVGYGDYVKTLTG (large-conductance calcium-activated potassium channel protein) IgG predominated in healthy controls. Of patients with AF, 16.2% presented anti-Kir3.4 autoantibodies compared with none in healthy controls. Next, we screened patients with no AF at baseline, but incident AF during follow-up. Table S3 lists the clinical characteristics and anti-Kir3.4 autoantibody status for each patient.

### Table 1. AF-Specific Autoantibody Reactivities in Plasma Samples

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Protein</th>
<th>Mean Pre/AF</th>
<th>Mean control</th>
<th>Mean difference</th>
<th>Unadjusted P value</th>
<th>FDR-adjusted P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IETETTIGYGFRTVEKCPE</td>
<td>Kir3.4</td>
<td>1.027</td>
<td>0.000</td>
<td>1.027</td>
<td>0.0138</td>
<td>0.0299</td>
</tr>
<tr>
<td>SNFTQLEDVFRRIFTYM</td>
<td>MRP</td>
<td>0.980</td>
<td>0.149</td>
<td>0.831</td>
<td>0.0450</td>
<td>0.0676</td>
</tr>
<tr>
<td>LMTVMSTVGYGDYVKTLTG</td>
<td>BKv</td>
<td>0.000</td>
<td>1.137</td>
<td>–1.137</td>
<td>0.0237</td>
<td>0.0712</td>
</tr>
</tbody>
</table>

Pre-AF vs control

| IETETTIGYGFRTVEKCPE    | Kir3.4   | 2.382       | 0.000        | 2.382           | 0.0199             | 0.0299               |
| LCIGYGRAPVGSDDWVLM     | HCN4     | 0.000       | 0.562        | –0.562          | 0.0841             | 0.0841               |
| SIHSFSSAFLEISDIVTIG     | Kir6.2   | 0.000       | 0.995        | –0.995          | 0.0239             | 0.0359               |
| LFKGKLYCSDSSKQTEAC     | Cn1,2    | 0.000       | 1.818        | –1.818          | 0.0017             | 0.0051               |

Table S3 lists the clinical characteristics and anti-Kir3.4 autoantibody status for each patient.

### K_{1.4} Autoantibody

To assess the role of K_{1.4} autoantibodies, we first purified the IgG out of plasma samples of patients with AF. We then tested the response of hiPSC-aCMCs to muscarinic cholinergic stimulation. The application of the agonist, 10 µmol/L carbachol, resulted in APD shortening by 21% (mean APD at 90% repolarization in control cells, 390.2±50.5 ms versus carbachol, 307±24.0 ms; *P*=0.157; Figure 2A and 2B; Table S4), thus confirming the presence of M_{3}-muscarinic receptors and K_{1.1/3.4} channels, which is in agreement with the literature. For *I_{k_{aCh}}* current recordings, the selective K_{2} channel blocker, ML-333, was used to discriminate between the inward rectifying K^+ currents’ contributions, *I_{k_{1}}* and *I_{k_{aCh}}*. A reversal potential around the equilibrium potential for K^+ was measured (–80 mV; Figure 2D). As expected, carbachol increased *I_{k_{aCh}}* current (at –120 mV, mean *I_{k_{aCh}}* in control cells, –6.9±2.3 pA/pF, versus carbachol, –11.8±1.2 pA/pF; *P*=0.040), thereby confirming the atrial phenotype of the cardiomyocytes. Figure 2 shows typical action potentials and *I_{k_{aCh}}* currents recorded in cells under control conditions and in response to muscarinic cholinergic stimulation. Next, we applied K_{1.4} autoantibodies extracted from patients with AF. Anti-K_{1.4} IgG shortened the APD by one-third (mean APD at 90% repolarization in control cells, 390.2±50.5 ms versus anti-K_{1.4} IgG, 261.5±17.5 ms; *P*=0.012; Figure 2A and 2B) and led to a 2-fold increase in *I_{k_{aCh}}* current (mean *I_{k_{aCh}}* at –120 mV in control cells, –6.9±2.3 pA/pF, versus anti-K_{1.4} IgG, –13.7±1.1 pA/pF; *P*=0.003; Figure 2C and 2D). The addition of carbachol did not further potentiate the effect of anti-K_{1.4} IgG (>0.05 when comparing anti-K_{1.4} IgG and anti-K_{1.4} IgG + carbachol). The mean cell capacitance did not differ between groups (*P*=0.970): control cells, 40.5±13.0 pF; with carbachol, 48.5±14.2 pF; with anti-K_{1.4} IgG, 35.8±5.1 pF; with anti-K_{1.4} IgG and carbachol, 62.6±25.8 pF. Table S4 summarizes the parameters of action potentials for each set of experiments.

### K_{3.4} Autoimmunity

Next, we developed an experimental mouse model of immunization to validate the arrhythmicogenic role of K_{3.4} autoantibodies in vivo (Figure 3A). After K_{3.4} immunization, all mice generated K_{3.4} autoantibodies (anti-K_{3.4} IgG titers >1:3000). Sham-immunized mice served as controls and accordingly presented no detectable titers. Two K_{3.4}-immunized mice died 1 week after full immunization and before completion of cardiac examinations. No previous progressive deterioration was observed. Nevertheless, the cause of death remains unknown. In general, all mice exhibited no signs of heart failure, such as edema or dyspnea. Body and heart weights were similar between groups (Table 2). K_{3.4} autoantibodies had no effect on cardiac structure or function (Table 2). All mice showed a preserved LV ejection fraction and normal left atrial dimensions on echocardiography (Table 2). Representative ECG traces are depicted in Figure 3B. All mice presented a normal sinus rhythm, and no differences in ECG intervals were found between groups (Figure 3B and 3C; Table S5). During intracardiac electrophysiological study, we recorded no changes in sinus and atrioventricular nodal function in the presence of K_{3.4} autoantibodies (Figure 3; Table S5). However, we measured a significantly shorter AERP in mice with K_{3.4} autoantibodies compared with...
control animals ($P=0.0012$; Figure 3E; Table S5). Because reduced AERP promotes multiple-circuit reentry in the atrial tissue, we next examined the susceptibility of each mouse to develop AF on rapid atrial pacing. Using standard burst pacing protocols, AF was inducible in 80% (8 of 10) of mice with Kir3.4 autoantibodies compared with 28% (4 of 14) in seronegative mice ($P=0.0361$; Figure 3D and 3F). Previous works have induced similar
Figure 3. Electrophysiological phenotyping of mice with K$_{3.4}$ autoantibodies.  
A, Study design of the experimental autoimmune AF model with Balb/c mice. B, Representative surface ECG traces derived from limb leads I and II, recorded from a sham-immunized and K$_{3.4}$-immunized mouse. C, Bar graphs overlaid with dot plots present mean ECG interval values±SD recorded in sham- (n=14) and K$_{3.4}$-immunized mice (n=10). Statistical significance was determined using the Student t test (PR, QRS, QTc, and JTc) and Mann-Whitney U test (RR). D, Representative bipolar intracardiac electrogram recordings at the level of the right ventricle (Continued)
rates of AF in control mice and on cholinergic activation with carbachol.\textsuperscript{26–31} Collectively, K$_{3,4}$ autoantibodies contribute to a 2.8-fold increased vulnerability to AF (relative risk, 2.8 [95% CI, 1.2–7.1]).

**DISCUSSION**

In the present study, we used a peptide microarray displaying the cardiac ion channel repertoire to establish the autoantibody profile of patients with AF. One single autoantibody targeting the extracellular site of the K$_{3,4}$ protein (IETETTIGYFRVITEKCPE peptide sequence; Figure S2) consistently discerned patients with AF from controls. Intriguingly, patients with pre-existent and incident AF during follow-up had in common the presence of K$_{3,4}$ autoantibodies. In an effort to explore further a potential link between K$_{3,4}$ autoantibodies and AF, we undertook cellular and animal studies. We first described K$_{3,4}$ autoantibody-induced reduction in atrial refractoriness, resulting in increased AF susceptibility.

In the past, studies have associated autoantibodies against myosin heavy chain, heat shock proteins, M$_{2}$-muscarinic acetylcholine, and b-adrenergic receptors with AF.\textsuperscript{4–6,8,9} Whereas anti–myosin heavy chain and anti–heat shock protein IgG have in fact been associated with AF but with no clear causal link, autoantibodies targeting the G protein–coupled receptors have essentially been the focus of autoimmune AF research.\textsuperscript{4–6} The autonomic nervous system initiates a sequence of signaling effects contributing to atrial structural and electrophysiological remodeling prone to AF.\textsuperscript{22,23} Nevertheless, in the present study, we also screened patients for the presence of anti–M$_{2}$-muscarinic and anti–b$_{1}$-adrenergic receptor autoantibodies but failed to detect any significant IgG reactivities to said receptors.

To the best of our knowledge, this is the first study to describe the existence of autoantibodies targeting a cardiac ion channel subunit, K$_{3,4}$, in AF. The K$_{3,4}$ target protein is of particular interest, given its atrial-selective expression.\textsuperscript{24} In the heart, K$_{3,4}$ forms a functional heterotrimer with the K$_{3,1}$ subunit, that underlies the acetylcholine–gated K$_{ACh}$ channel (formerly known as GIRK1/GIRK4 [G protein–activated inward rectifying K$^+$ channel]). The notion of altered inward rectifier K$^+$ currents in AF was first described >20 years ago.\textsuperscript{25} Although initial observations accounted I$_{K1}$ for AF; subsequent studies have pointed to the importance of I$_{KAC}$ current in the pathogenesis of AF.\textsuperscript{32,33} The I$_{KAC}$ pathway essentially mediates the negative chronotropic effect of the parasympathetic nervous system. The resulting shortened atrial APD, reduced AERP, and enhanced dispersion of atrial repolarization provide an arrhythmogenic substrate for AF.\textsuperscript{32,33,34} I$_{KAC}$ has 2 components, namely an acetylcholine–regulated and a constitutively active (agonist-independent) form. A sustained high atrial rate (atrial tachycardia) was found to increase the open probability of constitutively active I$_{KAC}$ channels that eluded the muscarinic cholinergic regulation.\textsuperscript{32,33} Together with Ca$^{2+}$ handling abnormalities, atrial contractility and conduction are impaired, giving way to reentry circuits and AF maintenance.\textsuperscript{35} Here, we discovered in patients with AF a K$_{3,4}$ autoantibody that increased I$_{KAC}$ in the absence of muscarinic cholinergic stimulation. This is the first report of an autoantibody-induced constitutive I$_{KAC}$ current.

Table 2. **Weight Parameters and Echocardiographic Data**

<table>
<thead>
<tr>
<th></th>
<th>Sham-immunized mice (n=14)</th>
<th>K$_{3,4}$-immunized mice (n=10)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BW, mean±SD, g</td>
<td>27.3±2.6</td>
<td>27.7±2.2</td>
<td>0.705</td>
</tr>
<tr>
<td>HW, mean±SD, mg</td>
<td>147±32.6</td>
<td>134.6±11.8</td>
<td>0.250</td>
</tr>
<tr>
<td>HW/TL, mean±SD, mg/mm</td>
<td>8.3±1.7</td>
<td>7.4±0.6</td>
<td>0.137</td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA, mean±SD, mm</td>
<td>2.3±0.2</td>
<td>2.3±0.2</td>
<td>0.989</td>
</tr>
<tr>
<td>AWd, mean±SD, mm</td>
<td>1.2±0.2</td>
<td>1.2±0.1</td>
<td>0.943</td>
</tr>
<tr>
<td>LVIDd, mean±SD, mm</td>
<td>3.4±0.4</td>
<td>3.1±0.4</td>
<td>0.198</td>
</tr>
<tr>
<td>PWd, mean±SD, mm</td>
<td>1.3±0.3</td>
<td>1.3±0.2</td>
<td>0.817</td>
</tr>
<tr>
<td>AWS, mean±SD, mm</td>
<td>1.7±0.2</td>
<td>1.6±0.2</td>
<td>0.097</td>
</tr>
<tr>
<td>LVIDs, mean±SD, mm</td>
<td>2.0±0.5</td>
<td>1.9±0.5</td>
<td>0.465</td>
</tr>
<tr>
<td>PWs, mean±SD, mm</td>
<td>1.6±0.3</td>
<td>1.6±0.3</td>
<td>0.853</td>
</tr>
<tr>
<td>FS, mean±SD, %</td>
<td>51.1±8.0</td>
<td>49.8±8.1</td>
<td>0.719</td>
</tr>
<tr>
<td>EF, mean±SD, %</td>
<td>76.7±11.6</td>
<td>78.7±11.9</td>
<td>0.676</td>
</tr>
</tbody>
</table>

Statistical significance was determined using the Student t test (BW, LA, LVIDd, PWd, AWS, LVIDs, PWs, FS, and EF) and Mann-Whitney U test (HW, TL, HW/TL, and AWd).

AWd indicates end-diastolic anterior wall thickness; AWs, end-systolic anterior wall thickness; BW, body weight; EF, ejection fraction; FS, fractional shortening; HW, heart weight; LA, left atria; LVIDd, end-diastolic left ventricular internal diameter; LVIDs, end-systolic left ventricular internal diameter; PWd, end-diastolic posterior wall thickness; PWs, end-systolic posterior wall thickness; and TL, tibia length.
This has prompted us to validate the findings in an experimental autoimmune model, in which mice were immunized to generate autoantibodies targeting \( I_{K_{ACh}} \) channels. In the same way that increased parasympathetic tone promotes AF, K\(_{3.4}\) autoantibodies in mice reduced atrial refractoriness, thus giving way to reentry wavelets and AF.\(^{28-31,41,42}\) The pathogenesis of AF is complex and essentially requires 2 critical components: a trigger that initiates the event and a substrate that maintains the arrhythmia.\(^{53}\) Consistent with this notion, we detected K\(_{3.4}\) autoantibodies in patients with no structural heart disease before AF manifests clinically. The presence of AF at baseline in these patients despite the absence of K\(_{3.4}\) autoantibodies may mean that a structural (eg, fibrosis or inflammation) or electrical substrate (tissue anisotropy secondary to heterogeneous atrial deposition of IgG) is required in addition to the \( I_{K_{ACh}} \) trigger to initiate AF. Future large cohorts will be important to determine the prevalence of autoimmune AF. In this sense, K\(_{3.4}\) autoantibody, as an independent AF risk factor, would present a powerful predictive blood biomarker for patients.

One limitation of the present study is that systematic prolonged ECG monitoring was not performed, raising the possibility that patients with AF but without clinical symptomatology were not accounted for in the analysis. We did not profile serially autoantibodies in any given patient and did not differentiate between AF types (paroxysmal, persistent, long-standing persistent, and permanent). We opted for a more lenient definition of unexplained AF rather than stringent (excluding patients with modifiable risk factors), given that a link between autoantibodies and cardiovascular risk factors has been established, and both conditions may coexist.\(^{43-45}\) Excluding patients with cardiovascular risk factors from our autoantibody screening would therefore have potentially introduced a selection bias. Moreover, microvesicles shed from cardiomyocytes after mechanical stress (cardiovascular risk factors) may release cell-specific proteins embedded in lipid bilayers into the systemic circulation and thus trigger an autoimmune response.\(^{46-49}\) Little is known about ion channels and their topology in microvesicles originating from cardiomyocytes. Considering that the \( I_{K_{ACh}} \)-forming heterotetramer is composed of 2 K\(_{3.4}\) and 2 K\(_{3.1}\) subunits, we would have expected the concomitant detection anti-K\(_{3.1}\) autoantibodies in patients with anti-K\(_{3.4}\) autoantibodies.\(^{50}\) On the basis of our peptide microarray assay, anti-K\(_{3.4}\) autoantibodies were not accompanied by anti-K\(_{3.1}\) autoantibodies (Pearson correlation coefficient, \( -0.04 \)). In addition, microvesicles originating from atrial cardiomyocytes would also cover atrial-specific K\(_{1.5}\) channels, but no matching IgG responses were detected (Pearson correlation coefficients comparing K\(_{3.4}\) and K\(_{1.5}\), \(-0.05 \) [RDERELLHRPPAHQPPAPA], \(-0.04 \) [APPSPGPT-VAPLLPRTLADPF], and \(-0.07 \) [NQGTHFSSIPDAFW-WAVVTM]). Altogether, the pathogenesis of circulating anti-K\(_{3.4}\) autoantibodies remains to be elucidated in future investigations. In our study, 3 patients presented anti-K\(_{3.4}\) autoantibodies in the absence of comorbidities. With that in mind, it is compelling to speculate that anti-K\(_{3.4}\) autoantibodies could also present a source for reentry through activation of \( I_{K_{ACh}} \) channels expressed in pulmonary veins.\(^{51}\) Furthermore, anti-K\(_{3.4}\) autoantibodies in the present study were polyclonal in nature. Further studies are needed to investigate whether a monoclonal population may account for the initiation of AF. Although widely used and accepted, the mouse model is imperfect for the study of AF due to the insufficient critical mass of the structurally normal murine heart that prevents sustained reentry circuits.\(^{29,30,52}\) For this reason, atrial pacing protocols have been introduced to use AF inducibility as a surrogate for human AF vulnerability. Likewise, we documented no spontaneous AF in K\(_{3.4}\)-immunized mice, but pacing-induced AF upon electrophysiological study.

Conclusions

We describe a novel, autoimmune form of AF that is caused by K\(_{3.4}\) autoantibodies, thus adding a new pathogenic mechanism to the long list of causes of AF. Future studies will be needed to investigate the therapeutic benefit of removing arrhythmogenic K\(_{3.4}\) autoantibodies from the circulation or of neutralizing antigen-binding sites of the antibody.\(^{5,6,53}\)

**ARTICLE INFORMATION**

**Disclosures**

Dr Tardif reports grants from Amarin; grants and personal fees from AstraZeneca; grants, personal fees, and minor equity interest from DaiCor; personal fees from HLS Pharmaceuticals; grants from Ionis; grants from Pfizer; personal fees from Pendopharm; grants from RegeneronBio; grants and personal fees from Sanofi; and personal fees from Servier, outside the submitted work. Dr Li reports previous employment by BioMarin Pharmaceutical Inc, outside the submitted work. Dr Maguy reports consultant fees from BioMarin Pharmaceutical Inc, outside the submitted work. The other authors report no conflicts.

**Sources of Funding**

This work was supported by an Ambizione and an Eccellenza grant from the Swiss National Science Foundation (P200P3_173961 to J.L. and P2CEP3_203333 to J.L.).

**Affiliations**

Institute of Physiology, University of Bern, Switzerland (A.M.), PEPperPRINT GmbH, Heidelberg, Germany (Y.M.), Montreal Heart Institute, Université de Montréal, Canada (J.-C.T., D.B.), Department of Cardiology, University Heart Center, University Hospital Zurich, University of Zurich, Switzerland (J.L.), Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland.

**Acknowledgments**

The authors thank the excellent support provided by the team of PEPperPRINT GmbH, in particular, Sarah Schott. We are indebted to Sandra Callet and Georgia Alaimo from BIOTEM for the outstanding collaboration on mice immunization. We thank Michael Känzig from the Institute of Physiology, University of Bern, for his invaluable technical assistance.

**References**

- 1. Alaimo from BIOTEM for the outstanding collaboration on mice immunization. We thank Michael Känzig from the Institute of Physiology, University of Bern, for his invaluable technical assistance.

- 2. Sources of Funding: This work was supported by an Ambizione and an Eccellenza grant from the Swiss National Science Foundation (P200P3_173961 to J.L. and P2CEP3_203333 to J.L.).

- 3. Disclosures: Dr Tardif reports grants from Amarin; grants and personal fees from AstraZeneca; grants, personal fees, and minor equity interest from DaiCor; personal fees from HLS Pharmaceuticals; grants from Ionis; grants from Pfizer; personal fees from Pendopharm; grants from RegeneronBio; grants and personal fees from Sanofi; and personal fees from Servier, outside the submitted work. Dr Li reports previous employment by BioMarin Pharmaceutical Inc, outside the submitted work. Dr Maguy reports consultant fees from BioMarin Pharmaceutical Inc, outside the submitted work. The other authors report no conflicts.

- 4. **ARTICLE INFORMATION**

  - Received October 6, 2022; accepted June 1, 2023.

- **Affiliations**

  - Institute of Physiology, University of Bern, Switzerland (A.M.), PEPperPRINT GmbH, Heidelberg, Germany (Y.M.), Montreal Heart Institute, Université de Montréal, Canada (J.-C.T., D.B.), Department of Cardiology, University Heart Center, University Hospital Zurich, University of Zurich, Switzerland (J.L.), Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland.

- **Acknowledgments**

  - The authors thank the excellent support provided by the team of PEPperPRINT GmbH, in particular, Sarah Schott. We are indebted to Sandra Callet and Georgia Alaimo from BIOTEM for the outstanding collaboration on mice immunization. We thank Michael Känzig from the Institute of Physiology, University of Bern, for his invaluable technical assistance.

- **Sources of Funding**

  - This work was supported by an Ambizione and an Eccellenza grant from the Swiss National Science Foundation (P200P3_173961 to J.L. and P2CEP3_203333 to J.L.).

- **Disclosures**

  - Dr Tardif reports grants from Amarin; grants and personal fees from AstraZeneca; grants, personal fees, and minor equity interest from DaiCor; personal fees from HLS Pharmaceuticals; grants from Ionis; grants from Pfizer; personal fees from Pendopharm; grants from RegeneronBio; grants and personal fees from Sanofi; and personal fees from Servier, outside the submitted work. Dr Li reports previous employment by BioMarin Pharmaceutical Inc, outside the submitted work. Dr Maguy reports consultant fees from BioMarin Pharmaceutical Inc, outside the submitted work. The other authors report no conflicts.
Supplemental Material

Expanded Methods

Tables S1–S5

Figures S1–S2

REFERENCES


